IE63097B1 - Method of reducing immunoglobulin e responses - Google Patents

Method of reducing immunoglobulin e responses

Info

Publication number
IE63097B1
IE63097B1 IE30289A IE30289A IE63097B1 IE 63097 B1 IE63097 B1 IE 63097B1 IE 30289 A IE30289 A IE 30289A IE 30289 A IE30289 A IE 30289A IE 63097 B1 IE63097 B1 IE 63097B1
Authority
IE
Ireland
Prior art keywords
human
monoclonal antibody
immunoglobulin
antagonist
human interleukin
Prior art date
Application number
IE30289A
Other languages
English (en)
Other versions
IE890302L (en
Inventor
Robert L Coffman
De Jan Egbert Vries
Original Assignee
Schering Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22538655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IE63097(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Biotech Corp filed Critical Schering Biotech Corp
Publication of IE890302L publication Critical patent/IE890302L/en
Publication of IE63097B1 publication Critical patent/IE63097B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IE30289A 1988-02-02 1989-01-31 Method of reducing immunoglobulin e responses IE63097B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15141388A 1988-02-02 1988-02-02

Publications (2)

Publication Number Publication Date
IE890302L IE890302L (en) 1989-08-02
IE63097B1 true IE63097B1 (en) 1995-03-22

Family

ID=22538655

Family Applications (1)

Application Number Title Priority Date Filing Date
IE30289A IE63097B1 (en) 1988-02-02 1989-01-31 Method of reducing immunoglobulin e responses

Country Status (20)

Country Link
US (1) US5676940A (fr)
EP (2) EP0397764A1 (fr)
JP (1) JPH03500050A (fr)
KR (1) KR900700132A (fr)
AT (1) ATE93144T1 (fr)
AU (1) AU629536B2 (fr)
CA (1) CA1341477C (fr)
DE (1) DE68908431T2 (fr)
DK (1) DK183590A (fr)
ES (1) ES2058490T3 (fr)
FI (1) FI903827A0 (fr)
HK (1) HK35196A (fr)
HU (1) HU211059B (fr)
IE (1) IE63097B1 (fr)
IL (1) IL89124A (fr)
MY (1) MY107079A (fr)
NZ (1) NZ227812A (fr)
PT (1) PT89573B (fr)
WO (1) WO1989006975A1 (fr)
ZA (1) ZA89766B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
AU648777B2 (en) * 1989-12-04 1994-05-05 Schering Corporation Method of treating septic shock
ZA9010190B (en) * 1989-12-20 1991-08-28 Schering Corp Antibody antagonists of human interleukin-4
US5252677A (en) * 1990-11-20 1993-10-12 Mitsubishi Petrochemical Company Limited Functionalized olefin polymers
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US20020193575A1 (en) * 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5597710A (en) * 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
EP3190126A1 (fr) 2000-05-26 2017-07-12 Immunex Corporation Utilisation d'anticorps contre le recepteur d'interleukine-4 (il-4r) et compositions correspondantes
PT1368028E (pt) 2001-03-12 2007-11-26 Avanir Pharmaceuticals Compostos de benzimidazole para modulação de ige e inibição da proliferação celular
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
AR050044A1 (es) 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
US10196616B2 (en) 2017-02-15 2019-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Altered avian virus for in-ovo inoculation and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
EP0255547A1 (fr) * 1986-07-29 1988-02-10 Kishimoto, Tadamitsu, Prof. Anticorps monoclonaux spécifiques du récepteur de surface pour IgE, ainsi que des lignes de cellules hybrides produisant ces anticorps et leur utilisation
JP2724625B2 (ja) * 1987-12-31 1998-03-09 タノックス・バイオシステムズ・インコーポレーテッド ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基

Also Published As

Publication number Publication date
MY107079A (en) 1995-09-30
JPH03500050A (ja) 1991-01-10
CA1341477C (fr) 2005-03-29
DK183590D0 (da) 1990-08-01
EP0327283A1 (fr) 1989-08-09
ZA89766B (en) 1989-09-27
FI903827A0 (fi) 1990-08-01
PT89573A (pt) 1989-10-04
EP0397764A1 (fr) 1990-11-22
EP0327283B1 (fr) 1993-08-18
PT89573B (pt) 1994-01-31
ES2058490T3 (es) 1994-11-01
WO1989006975A1 (fr) 1989-08-10
DE68908431D1 (de) 1993-09-23
DE68908431T2 (de) 1993-12-23
AU629536B2 (en) 1992-10-08
HU891044D0 (en) 1990-11-28
HK35196A (en) 1996-03-08
NZ227812A (en) 1991-09-25
KR900700132A (ko) 1990-08-11
IL89124A0 (en) 1989-08-15
ATE93144T1 (de) 1993-09-15
HU211059B (en) 1995-10-30
AU3038389A (en) 1989-08-25
US5676940A (en) 1997-10-14
IE890302L (en) 1989-08-02
HUT54214A (en) 1991-01-28
DK183590A (da) 1990-09-27
IL89124A (en) 1994-10-21

Similar Documents

Publication Publication Date Title
EP0327283B1 (fr) Méthode visant à réduire la réponse immunitaire à l'immunoglobuline E
EP1003781B1 (fr) Proteines de fixation de l'interleukine-18, leur preparation et utilisation
KR100483494B1 (ko) 감마 인터페론에 대한 인간화 항체
US5096704A (en) Method of treating eosinophilia
US20070081975A1 (en) Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
CA2002144C (fr) Methode de prevention ou de reduction de l'eosinophilie
EP0504307B1 (fr) Methode de traitement de choc septique
AU650013B2 (en) BCRF1 antagonists for treating Epstein-Barr virus infections

Legal Events

Date Code Title Description
MM4A Patent lapsed